Medeze Group PCL (BKK:MEDEZE) EBIT: ฿166.2 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:MEDEZE Medeze Group PCL BKK:MEDEZE
19 GF Score
Price ฿6.20
! 5 Warning Signs
View Full Analysis

What is Medeze Group PCL EBIT?

Medeze Group PCL BKK:MEDEZE -1.59% 19 EBIT is ฿166.2 Mil as of Jun. 2026. GuruFocus rates BKK:MEDEZE with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Medeze Group PCL's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was ฿44.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ฿166.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medeze Group PCL's annualized ROC % for the quarter that ended in Jun. 2026 was 7.49%. Medeze Group PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 26.08%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medeze Group PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 3.27%.

Medeze Group PCL  (BKK:MEDEZE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medeze Group PCL's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=137.964 * ( 1 - 0% )/( (1789.746 + 1892.56)/ 2 )
=137.964/1841.153
=7.49 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3538.947 - 58.42 - ( 1690.781 - max(0, 118.742 - 1810.608+1690.781))
=1789.746

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3488.895 - 42.942 - ( 1553.393 - max(0, 100.355 - 1694.074+1553.393))
=1892.56

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Medeze Group PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=176.992/( ( (656.644 + max(3.158, 0)) + (651.272 + max(46.139, 0)) )/ 2 )
=176.992/( ( 659.802 + 697.411 )/ 2 )
=176.992/678.6065
=26.08 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(47.789 + 35.06 + 30.809) - (58.42 + 28.963 + 23.117)
=3.158

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(68.27 + 34.625 + 35.193) - (42.942 + 34.163 + 14.844)
=46.139

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medeze Group PCL's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=166.169/5084.181
=3.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeze Group PCL EBIT Related Terms

Medeze Group PCL EBIT Historical Data

* Premium members only.

The historical data trend for Medeze Group PCL's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeze Group PCL EBIT Chart

Medeze Group PCL Annual Data
Trend Dec23 Dec24 Dec25
EBIT
310.31 387.08 250.88

Medeze Group PCL Quarterly Data
Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 73.18 40.96 41.99 38.98 44.25

BKK:MEDEZE vs HCA, THC, EHC: EBIT Comparison

For the Medical Care Facilities subindustry, Medeze Group PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medeze Group PCL EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Medeze Group PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medeze Group PCL's EV-to-EBIT falls into.


BKK:MEDEZE
19GF Score
Medeze Group PCL BKK:MEDEZE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medeze Group PCL EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿166.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ฿166.2 Mil mean?
Medeze Group PCL (BKK:MEDEZE) has a EBIT of ฿166.2 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medeze Group PCL.
Is Medeze Group PCL's EBIT too high?
Medeze Group PCL's current EBIT is ฿166.2 Mil. Overall, Medeze Group PCL has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Medeze Group PCL's EBIT compare to HCA and THC?
Medeze Group PCL's EBIT of ฿166.2 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medeze Group PCL. Medeze Group PCL's current EBIT is ฿166.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeze Group PCL stock overvalued right now?
Medeze Group PCL (BKK:MEDEZE) has a current EBIT of ฿166.2 Mil. The current EBIT is ฿166.2 Mil. Medeze Group PCL's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medeze Group PCL (BKK:MEDEZE), the current EBIT is ฿166.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medeze Group PCL Business Description

Address Phuttha Monthon Sai 4 Road, 28/9 Moo 8, Krathum Lom, Sam Phran, Nakhon Pathom, THA, 73220
Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment. Geographically, the company operates in Thailand, Vietnam, Cambodia, Philippines, and Other countries, of which maximum revenue is derived from Thailand.
19GF Score

Get the complete analysis for BKK:MEDEZE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿6.20
Price